Nursing Interventions for Glycemic Control
14. juni 2018 oppdatert av: Ana Elizabeth Prado Lima Figueiredo, Pontificia Universidade Católica do Rio Grande do Sul
Introduction: Diabetes mellitus (DM) is a very frequent pathology, which can lead to renal failure and the need for renal replacement therapy.
In people with chronic kidney disease (CKD) and diabetes mellitus (DM), glycemic control is very important for the prevention of microvascular injury.
In this context, the Nursing Process (NP) is the instrument to guide care, contributing to the attention of individuals' needs.
Objective: To evaluate the results of Nursing Outcomes Classification (NOC), obtained through interventions of the Nursing Interventions Classification (NIC) for the glycemic control, in patients with diabetes in renal replacement therapy, with a diagnosis of Unstable Glycemia, of the North American Nursing Diagnosis - International (NANDA-I).
Method: Randomized clinical trial in three dialysis services in southern Brazil.
Population: Type I and II diabetes patients on hemodialysis.
Sample: Over 18 years old, literate, who accept to participate in the study by signing a Term of Consent Free and Clarified.
Exclusion criteria: severe uncorrected deficiency in hearing, speech, total amaurosis, degenerative neurological diseases, or score less than 20 in the Mini Mental State Examination.
Randomization occurred by clusters, considering dialysis shifts.
The CG followed routine treatment and guidelines, while the IG received nursing interventions on a monthly basis for 6 months.
Variables related to NOC scores and the knowledge, attitude and self-care tests for DM were applied before and after the intervention period.
After the intervention period, a washout period of 06 months will occur, after which the variables will be collected.
Studieoversikt
Status
Ukjent
Forhold
Intervensjon / Behandling
Detaljert beskrivelse
After randomization, the intervention group was assesses by a nurse determining the nursing outcomes (NOC)for the specific nursing diagnosis Unstable glycemia. One educational intervention per month was done:
- Teaching: individual and Teaching: disease process.
- Control of hyperglycemia and Control of hypoglycemia.
- Teaching: prescription drugs (prescription drugs, was carried out focusing on oral hypoglycemic agents and insulin)
- Teaching: psychomotor skills ( was performed with a view to the management and application of insulin). In case of use oral antiglycemic agent the Teaching: prescription drugs and control of hyperglycaemia and hypoglycemia was repeated
- Teaching: Foot care.
- Teaching: activity / prescribed exercises. After the completion of the six intervention patients were assessed for outcome classification the study will contemplate a 6 months washout between the NOC assessment ( end of interventions and final assessment)
Studietype
Intervensjonell
Registrering (Faktiske)
74
Fase
- Ikke aktuelt
Kontakter og plasseringer
Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.
Studiesteder
-
-
Rio Grande Do Sul
-
Porto Alegre, Rio Grande Do Sul, Brasil, 90.619-900
- Pontificia Universidade Católica Rio Grande do Sul
-
-
Deltakelseskriterier
Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
18 år og eldre (Voksen, Eldre voksen)
Tar imot friske frivillige
Nei
Kjønn som er kvalifisert for studier
Alle
Beskrivelse
Inclusion Criteria:
- diabetic with chronic kidney disease on hemodialysis
- over 18 years old
- literate,
- who accept to participate in the study by signing a Term of Consent Free and Clarified
Exclusion Criteria:
- severe uncorrected deficiency in hearing, speech,
- total amaurosis,
- degenerative neurological diseases,
- score less than 20 in the Mini Mental State Examination
Studieplan
Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Enkelt
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Ingen inngripen: Control
Patients have not received any special intervention, the follow up care was the standard care for the specific clinic
|
|
|
Eksperimentell: Intervention
After initial allocation the select patient received six educational interventions selected from Nursing Intervention Classification (NIC)
|
Andre navn:
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Glycemic control - HbA1< 7%
Tidsramme: 1 year
|
blood sample after NIC interventions
|
1 year
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Improve Knowledge assessed by questionaries DKNA
Tidsramme: 1 year
|
DKNA has 15 multiple choice response items and covers aspects related to the general knowledge of diabetes mellitus. The questions are about basic physiology, food groups and substitutions, DM management in case of complications, and general principles of disease care). The measurement scale used is from 0 to 15. A score (1) is assigned for correct answer and zero (0) for incorrect. Score greater than eight indicates knowledge about diabetes mellitus |
1 year
|
Andre resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Improve attitude and coping of Diabetes assessed by questionaries ATT-19
Tidsramme: 1 year
|
ATT - 19, it is an instrument that seeks the psychological adjustment measure for diabetes mellitus, developed as a response to the needs of evaluation of psychological and emotional aspects of the disease.
It contains nineteen items that include six factors: a) stress associated with DM, b) receptivity to treatment, c) trust in treatment, d) personal efficacy, e) health perception, f) social acceptance, whose responses are measured through five-point Likert scale (I totally disagree - score 1, until I fully agree - score 5).
The total value of the score varies from from 19 to 95 points.
A score greater than 70 points indicates a positive attitude about the disease
|
1 year
|
Samarbeidspartnere og etterforskere
Det er her du vil finne personer og organisasjoner som er involvert i denne studien.
Etterforskere
- Hovedetterforsker: Claudia Capellari, Master, Pontificia Universidade Católica do Rio Grande do Sul
- Hovedetterforsker: Ana Figueiredo, PhD, Pontificia Universidade Católica do Rio Grande do Sul
Studierekorddatoer
Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.
Studer hoveddatoer
Studiestart (Faktiske)
1. november 2016
Primær fullføring (Faktiske)
1. mai 2018
Studiet fullført (Forventet)
1. august 2018
Datoer for studieregistrering
Først innsendt
30. april 2018
Først innsendt som oppfylte QC-kriteriene
14. juni 2018
Først lagt ut (Faktiske)
15. juni 2018
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
15. juni 2018
Siste oppdatering sendt inn som oppfylte QC-kriteriene
14. juni 2018
Sist bekreftet
1. juni 2018
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- EnfDiaTrial
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
NEI
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Nei
Studerer et amerikansk FDA-regulert enhetsprodukt
Nei
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .